The FDA will delay its decision on Shire's experimental drug Elaprase for Hunter's syndrome so that it can consider additional data. A decision is now expected by August 24, which Shire says will allow it to start marketing the drug in the latter part of this year. Hunter's syndrome is a rare genetic disorder that afflicts about 2,000 people worldwide.
- read the AP's report on Elaprase